Opthea Ltd - Kewajiban jangka dawa perusahaan OPT

Opthea Limited (OPT) is optimizing the delivery of biologics through a distributed network of cold storage warehouses to mitigate the risk of disruptions. However, the business faces high risk due to its reliance on a single macular degeneration drug, where the indicator stands at 0.00. This chart of debt obligation value changes demonstrates the financial profile of Opthea Limited (OPT). The firm is currently funded by investments as it develops retinal therapy drugs within clinical trials.

Opthea Limited competes with biopharmaceutical behemoths by implementing an innovative combination therapy for the treatment of macular degeneration. This indicator captures the total liabilities with a maturity of more than one year, reflecting the long-term debt load. By analyzing changes in the company's long-term debt, an investor assesses the stability of the liability structure. An increase in this metric may indicate the financing of R&D projects; however, excessive loans increase the cost of capital and financial risks.